Go to content
Koninklijke Philips N.V.

Koninklijke Philips N.V.

Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.

Publicatie datum 20 aug 2008 - 10:14
Statutaire naam Koninklijke Philips N.V.
Titel Philips to lead 'euHeart' project for highly personalized diagnosis and treatment of cardiovascular disease
Bericht August 20, 2008 PHILIPS TO LEAD 'EUHEART' PROJECT FOR HIGHLY PERSONALIZED DIAGNOSIS AND TREATMENT OF CARDIOVASCULAR DISEASE Amsterdam, the Netherlands - Royal Philips Electronics (NYSE: PHG, AEX: PHI) today announced that it will lead a new European Union (EU) funded research project called 'euHeart,' which is aimed at improving the diagnosis, therapy planning and treatment of cardiovascular disease – one of the biggest causes of mortality in the western world. The euHeart consortium comprises public and private partners from 16 research, academic, industrial and medical organizations from six different European countries. It will run for four years and has a budget of approximately EUR 19 million, of which approximately EUR 14 million will be provided by the European Union. By targeting the diagnosis and treatment phases of the care cycles for heart conditions such as heart failure, coronary artery disease, heart rhythm disorders, and congenital heart defects, the euHeart project complements the recently announced HeartCycle project, also led by Philips, which focuses on the long term management of chronic heart disease patients. The euHeart consortium aims to develop advanced computer models of the human heart that can be personalized to patient-specific conditions using clinical data from various sources, such as CT (Computed Tomography) and MRI (Magnetic Resonance Imaging) scans, measurements of blood flow and blood pressure in the coronary arteries (which feed the heart muscles) and ECGs (Electrocardiograms). These computer models will integrate the behavior of the heart and the aorta at molecular, cellular, tissue and organ-level. They will also incorporate clinical knowledge about how cardiovascular disease disturbs the correct functioning of the heart at these levels. As a result, it may be possible to develop simulation tools that doctors can use to predict the outcome of different types of therapy, and because the models will be personalized to indiv

Datum laatste update: 08 februari 2025